| Topic | Issue # |
| Aaron Diamond Research Center | 384 |
| Abbreviated Guide ... HIV | 380 |
| Access to care | 387 |
| Achmat, Zackie | 387 |
| ACT UP | 385 |
| ACTG 384 trial changes | 382 |
| Activism | 377, 379, 385, 387 |
| ADAP crisis | 380, 381, 382, 386, 387 |
| ADAP waiting list advice | 381 |
| Advocacy | 387 |
| African Services Committee | 385 |
| AIDS Drug Assistance Program | (see ADAP) |
| AIDSWatch lobbying | 380 |
| Amprenavir approved | 378 |
| Anti-HIV factor | 384 |
| Atazanavir | 379 |
| Avascular necrosis | 379 |
| Barcelona conference take-home messages | 382 |
| Barcelona conference visa problems | 381 |
| Barcelona conference Web sites | 381 |
| Barcelona online reports | 382 |
| Benefits issues | 377 |
| Bone problems | 379 |
| Buyers' club list | 387 |
| Chinese activist, Dr. Wan Yanhai | 383 |
| Coca-Cola protest | 384 |
| Conferences and meetings list | 378 |
| Congress | 387 |
| Cost of international conferences | 381 |
| Counterfeit drugs | 380 |
| C-Reactive Protein | 385 |
| d4T -- side effects | 378 |
| d4T and lipoatrophy | 378 |
| Deca Durabolin availability problems | 381 |
| Defensins | 384 |
| Doctors Without Borders | 385 |
| Doha, Qatar | 386 |
| Drug interactions | 377 |
| Drug pricing | 377 |
| Efavirenz once daily | 378 |
| Epogen | 380 |
| Facial injections | 378 |
| Fundraising | 377 |
| Fuzeon | (see T-20) |
| Global Fund | 379 |
| Government AIDS Web site | 386 |
| Grossman, Dr. Howard, interview | 383 |
| Guidelines on metabolic complications | 385 |
| Health GAP | 385 |
| Heart disease prevention | 377 |
| Heart disease | 385 |
| Hepatitis C | 384 |
| HIV harm reduction | 384 |
| ICAAC conference, clinical trials | 384 |
| Integrase inhibitor | 379 |
| Intellectual property | 385, 386 |
| Interactions of drugs | 377 |
| Johns Hopkins short guide | 380 |
| Junk foods | 377 |
| Kaiser, Jon, M.D. | 383 |
| Lactic acidosis | 378 |
| Legal issues | 377 |
| Lipoatrophy -- drug changes | 378 |
| Lipodystrophy strategies | 383 |
| Marijuana lung report | 385 |
| Marijuana | 379 |
| Measles may suppress HIV | 379 |
| Medicaid crisis | 387 |
| Medicaid funding | 380 |
| Medical privacy rules | 379 |
| Medical research funding | 377 |
| Metabolic complications -- guidelines | 385 |
| MSF (Doctors Without Borders) | 385 |
| Nandrolone availability problems | 381 |
| Nandrolone generic | 382 |
| NATAF conference | 382 |
| NDRI (National Disease Research Interchange) | 385 |
| Network of People ... Nigeria | 385 |
| Neuromuscular weakness | 378 |
| Nevirapine patient assistance program | 385 |
| New drugs at Retroviruses conference | 379 |
| Nigeria -- patent meeting | 385 |
| Nonoxynol-9 dangers | 381 |
| Nonoxynol-9 dangers | 384 |
| Once-a-day dosing | 383 |
| Oxfam | 385 |
| Patents on pharmaceuticals | 385, 386 |
| Patient assistance programs | 385 |
| Peginterferon (hepatitis C) | 384 |
| PHATAM (Pan African HIV/AIDS Treatment Access Movement) | 383 |
| Philadelphia, AIDS Education Month | 380 |
| Political organizing | 387 |
| Prevention -- tenofovir | 385 |
| Pricing of drugs | 377 |
| Protease inhibitors | 383 |
| Remune controversy | 380 |
| Resistance testing | 383 |
| Retroviruses conference | 378, 387 |
| Retroviruses conference, Web coverage | 378 |
| Ribavirin (hepatitis C) | 384 |
| S-1360 integrase inhibitor | 379 |
| Search for a Cure | 387 |
| Serostim | 380 |
| Smallpox vaccination begins | 386 |
| Smallpox vaccination questions | 387 |
| Superinfection risk | 383 |
| T-20 | 383, 384 |
| Tenofovir access in poor countries | 386 |
| Tenofovir for prevention | 385 |
| Tenofovir | 377, 383 |
| Tipranavir | 379 |
| Tissue donation | 385 |
| TMC125 | 379 |
| Topoisomerase inhibitors | 379 |
| Treatment Action Movement of Nigeria | 385 |
| Treatments, misc. experimental | 377 |
| U.S. government AIDS Web site | 386 |
| Vaccine Research Center, NIAID | 385 |
| Vaccine trial | 385 |
| Viread | 377 |
| Visa problems | 381 |
| Wan Yanhai released | 384 |
| Wan Yanhai | 383 |
| WTO trade rules | 386 |
E-Mail
Printable Single-Page
Glossary
Share
